Ascendis Pharma

Ascendis Pharma

https://ascendispharma.com/
Tags:DevelopmentDrugFashionGrowthHumanITPharmacyProductScienceTechnology
Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies. Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development. The company continues to expand into additional therapeutic areas to address unmet patient needs. Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey.
Location: Denmark, Capital Region of Denmark, Gentofte Municipality
Member count: 501-1000
Total raised: $168M
Founded date: 2007

Investors 7

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
29.01.2015IPO$108M--
01.12.2014Series D$60M--

Mentions in press and media 54

DateTitleDescriptionCategoryAuthorSource
13.03.2022Ascendis P...– For the primary composite en...--globenewsw...
02.03.2022Ascendis P...- Top-line results from PaTHwa...--globenewsw...
25.02.2022Ascendis P...COPENHAGEN, Denmark, Feb. 25, ...--globenewsw...
11.02.2022Ascendis P...COPENHAGEN, Denmark, Feb. 10, ...--marketscre...
10.02.2022Ascendis P...COPENHAGEN, Denmark, Feb. 10, ...--globenewsw...
13.01.2022Ascendis P...COPENHAGEN, Denmark, Jan. 13, ...--globenewsw...
10.01.2022Ascendis P...COPENHAGEN, Denmark, Jan. 10, ...--globenewsw...
04.01.2022Ascendis P...COPENHAGEN, Denmark, Jan. 04, ...--globenewsw...
04.01.2022Ascendis P...COPENHAGEN, Denmark, Jan. 04, ...--marketscre...
14.12.2021Ascendis P...–– TransCon™ PTH Phase 3 topli...--globenewsw...
Show more